Last reviewed · How we verify

NCT04005625: FUMBLE

Biotherapy Treatment on Features of Microcrystalline Polyarthritis

Completed Last updated 14 September 2020
What this trial tests

trial in Crystal-Induced Arthritis in 46 participants. Completed in 1 June 2020.

Timeline
1 May 2019
Primary endpoint
1 June 2020
1 June 2020

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusCompleted
Study typeOBSERVATIONAL
Enrollment46
Start date1 May 2019
Primary completion1 June 2020
Estimated completion1 June 2020
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

Eligibility, any sex, with Crystal-Induced Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will involve adult patient who had received any biologic agent for microcrystalline disease in western France (Tours, Le Mans, Orléans, Angers, Rennes, Poitiers et Brest) between 01/01/2010 and 31/12/2018. Investigators will answer retrospectively a questionnaire that covers patient and disease data, biologic agent use, efficacy and adverse events.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04005625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing